Recombinant human growth hormone enhances the metabolic efficacy of parenteral nutrition: a double-blind, randomized controlled study
- PMID: 1548352
- DOI: 10.1210/jcem.74.4.1548352
Recombinant human growth hormone enhances the metabolic efficacy of parenteral nutrition: a double-blind, randomized controlled study
Abstract
This multicenter, randomized, double-blind study was performed to investigate whether recombinant GH improves the efficacy of total parenteral nutrition (TPN). Fifteen stable patients requiring parenteral feeding due to gastrointestinal/pancreatic disease were studied. Constant maintenance TPN providing approximately 30 kcal/kg day and approximately 1.6 g protein/kg.day was administered during an initial 7-day baseline period. After randomization, daily sc injections of saline (control, n = 9) or GH (10 mg/day, n = 6) were administered a 14-day treatment period as nutrient intake remained constant. Elemental balances for nitrogen (N), potassium (K), phosphorus (P), and sodium (Na) were determined daily and serial blood indices, vital signs, and other clinical parameters were monitored. Nutrient balances approached equilibrium during the baseline week in both groups. With GH administration, a significant increase in N, K, and P balance occurred; in contrast, nutrient balances did not change significantly from baseline values in control patients. The cumulative change (delta) in nutrient balances from the baseline week was also significantly greater in the GH-treated patients (delta N: control+2 +/- 7 g vs. GH+36 +/- 6. g, P less than 0.005; delta K:+57 +/- 45 mmol vs.+199 +/- 19 mmol, P less than 0.03; delta P: -27 +/- 30 mmol vs. +91 +/- 69 mmol, P less than 0.02). Plasma insulin-like growth factor-I concentrations rose 5-fold and serum cholesterol rose slightly with GH; no other significant change in group mean blood values occurred. One patient receiving GH and chronic prednisone therapy developed moderate hyperglycemia and mild peripheral edema; no other deleterious effects attributable to GH were observed. GH was well tolerated and significantly enhanced nutrient retention compared to standard parenteral feeding alone. GH improves the efficacy of parenteral nutrient utilization in patients requiring TPN.
Similar articles
-
Does growth hormone allow more efficient nitrogen sparing in postoperative patients requiring parenteral nutrition? A double-blind, placebo-controlled randomised trial.Clin Nutr. 2005 Dec;24(6):943-55. doi: 10.1016/j.clnu.2005.06.006. Epub 2005 Aug 3. Clin Nutr. 2005. PMID: 16083996 Clinical Trial.
-
Metabolic effects of recombinant human growth hormone in patients receiving parenteral nutrition.Ann Surg. 1988 Jul;208(1):6-16. doi: 10.1097/00000658-198807000-00002. Ann Surg. 1988. PMID: 3133995 Free PMC article.
-
Use of human growth hormone combined with nutritional support in a critical care unit.JPEN J Parenter Enteral Nutr. 1990 Nov-Dec;14(6):574-81. doi: 10.1177/0148607190014006574. JPEN J Parenter Enteral Nutr. 1990. PMID: 2273531
-
Effects of insulin-like growth factor-I and growth hormone in models of parenteral nutrition.JPEN J Parenter Enteral Nutr. 1999 Nov-Dec;23(6 Suppl):S184-9. doi: 10.1177/014860719902300603. JPEN J Parenter Enteral Nutr. 1999. PMID: 10571453 Review.
-
Recent advances: parenteral nutrition support.Ann Pharmacother. 1995 Feb;29(2):174-80. doi: 10.1177/106002809502900213. Ann Pharmacother. 1995. PMID: 7756717 Review.
Cited by
-
Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.J Clin Invest. 1993 Feb;91(2):391-6. doi: 10.1172/JCI116212. J Clin Invest. 1993. PMID: 7679407 Free PMC article.
-
Effects of recombinant human growth hormone on remnant liver after hepatectomy in hepatocellular carcinoma with cirrhosis.World J Gastroenterol. 2004 May 1;10(9):1292-6. doi: 10.3748/wjg.v10.i9.1292. World J Gastroenterol. 2004. PMID: 15112344 Free PMC article. Clinical Trial.
-
Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions.J Endocrinol Invest. 1998 Feb;21(2):115-21. doi: 10.1007/BF03350325. J Endocrinol Invest. 1998. PMID: 9585386
-
The role of insulin, growth hormone and IGF-I as anabolic agents in the critically ill.Intensive Care Med. 1993;19 Suppl 2:S54-7. doi: 10.1007/BF01708801. Intensive Care Med. 1993. PMID: 7508957 Review. No abstract available.
-
Short-term application of low-dose growth hormone in surgical patients: effects on nitrogen balance and blood glucose.World J Gastroenterol. 2007 Jan 21;13(3):452-6. doi: 10.3748/wjg.v13.i3.452. World J Gastroenterol. 2007. PMID: 17230618 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials